English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The combination of piperacillin and tazobactam has been shown to be efficacious for the treatment of intra-abdominal infections, skin and soft tissue infections, bacteraemia and pneumonia. The pharmacokinetics (PK) of piperacillin/tazobactam have been extensively investigated in both healthy volunteers and in distinct patient settings. 1 Like other b-lactams, piperacillin/tazobactam displays time-dependent pharmacodynamics (PD), whereby duration of time that concentrations remain above the MIC correlates best with bacterial kill and efficacy. The PK/PD target associated with a high probability of therapeutic success is defined as free concentrations above the MIC for 50% of the dosing interval (50% fT .MIC). 2 In case of more severe infections or when poor penetration into infected tissues is expected, 30%‐ 40% fT . 4‐5 ×MIC should ideally be attained. 2 It is not clear whether these targets are reached in morbidly obese patients as published information on optimal dosing in this subset of patients is rare. A 33-year-old morbidly obese patient (220 kg, 1.9 m and body mass index 55 kg/m 2 ) was transferred to our orthopaedic ward with a surgical site infection following a transfemoral amputation of the left leg following a car accident. He has provided written, informed consent for the details given here to be published. The patient had been empirically started on amoxicillin/ clavulanic acid; however, despite 8 days of treatment, necrosis increased and markers of infection were still raised (C-reactive

Dosing of piperacillin/tazobactam in a morbidly obese patient